Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

• Main Authors: Yi Qian (Author), Lu-Ning Sun (Author), Yang-Jie Liu (Author), Qiang Zhang (Author), Jiang-Hao Xu (Author), Zeng-Qing Ma (Author), Xue-Hui Zhang (Author), Hao Xu (Author), Yong-Qing Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters on unbound imatinib and its active metabolite N...